Cancer Surgery Performed in SpainWorld First Use of Lightpoint's SENSEI(R) Drop-In Gamma Probe in Bladder Cancer SurgeryPerformed in Spain LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Lightpoint Surgical Limited (Lightpoint), anaffiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announcesa world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI(R) , Telix'sminiature robotic-assisted gamma probe used to detect radiation in patients and guidesurgery. The patient was operated on at Hospital del Mar in Barcelona, Spain. SENSEI(R) is smaller than an AA battery and designed specifically for robotic-assistedand minimally invasive surgery. The miniature size and proprietary features make thetechnology ideal for tight surgical spaces such as around the bladder. With broad application in radio-guided surgery across multiple procedures and majorcancer types, SENSEI(R) is currently indicated for use during SLN biopsy in prostate,endometrial and cervical cancers. As part of an investigator-initiated clinical trial,SENSEI(R) was used by Dr. Llu?s Cecchini with the da Vinci Xi surgical robotic platformin a patient scheduled for radical cystectomy and Bricker urinary diversion with SLNbiopsy. Dr. Llu?s Cecchini, Head of Urology at Hospital del Mar said, "Lymph nodes around thebladder have a high chance of being cancerous and are therefore important to excise.Radio-guided surgery has historically been limited by the fact that gamma probes aregenerally only suitable for open surgery. The size and flexibility of SENSEI(R) meant itwas easy to manipulate within the surgical cavity, see the gamma signal within therobotic console, and quickly locate the SLN, where I might otherwise not have known itwas present. Being able to perform the procedure with minimal impact on surroundinghealthy tissue is a high surgical priority. With SENSEI(R) we can deliver a moretargeted, focused, and less complex experience for patients." Nynke van den Berg, General Manager Medical Technologies (MedTech) at Telix added, "Afirst bladder cancer procedure with the SENSEI(R) drop-in gamma probe is a significantmilestone for Telix and the Lightpoint team. As we focus on aligning SENSEI(R) with ourIlluccix(R) and TLX599-CDx programs for prostate cancer, this successful proceduredemonstrates the potential and scope to expand use into other urologic malignancies -- inline with our portfolio approach to support the patient from diagnosis to surgicalintervention and therapy." About SENSEI(R) Lightpoint has developed SENSEI(R) - a miniaturised surgical gamma probe for minimallyinvasive and robot-assisted surgery. The device is approved for sale in the US, EU, UK,and Australia and is in clinical use in the US, UK, Germany, France, Netherlands,Belgium, and Spain. About Lightpoint Lightpoint Surgical Ltd (Lightpoint) is an affiliate of Telix Pharmaceuticals Limited.As the MedTech division of Telix, Lightpoint is focused on the development ofprecision-guided surgical solutions and complementary Artificial Intelligencetechnologies to aid detection, management and treatment of cancer and rare diseases.Lightpoint is headquartered in the United Kingdom. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email:
[email protected] 
(20min delay)